Pipeline
ADEL-Y04
ADEL-Y04
ApoE4 antibody
Target Type
ApoE4
Indication
Alzheimer’s Disease,
Metabolic disease
Development stage
Preclinical efficacy
Target
Apolipoprotein E4 (ApoE4)
- The strongest genetic risk factor for AD (two copies of the ApoE4 variant increase the risk by up to 12 times)
Lane CA et al., Eur. J. Neurol. 25(1): 59, 2018)
- Aggravates b-amyloid accumulation and tau pathology
- Has a higher propensity for self-aggregation and less efficient in lipid metabolism compared to the E3 and E2 variants
- Known to induce inflammation, damage the blood-brain barrier, and increase the risk of heart disease.
Summary
Reduce tau and inflammation and improve synapses and cognitive dysfunction in ApoE4-expressing AD model
Competitive advantages
- Binds specifically to ApoE4 protein
- High binding affinity to ApoE4 aggregates compared to competitive anti-ApoE4 antibody
Development stage
- Obtain a clone
- In vivo safety and efficacy
- Pipelines
- Discovery
- Preclinical
- Clinical
ADEL-Y04
ApoE4-target